Friday, March 29, 2024
Home > Merck

Merck Q1 2023 Report Shows Revenue Drop as COVID Treatment Sales Crash, MRK Stock Down 1%

Affected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report. Multinational pharmaceutical giant Merck & Co Inc (NYSE: MRK) has released its Q1 2023 report. The company’s figures show a reduction in revenue due to several factors, including a plunge in

Read More

Merck Seals $425M Buyout Deal with OncoImmune for COVID-19 Drug

The deal with OncoImmune will see Merck take up the ownership of CD24Fc with additional payment made to OncoImmune based on future favorable regulatory approvals associated with the drug.American multinational pharmaceutical company Merck & Co Inc (NYSE: MRK) has inked a $425 million deal with OncoImmune, a privately-held, clinical-stage biopharmaceutical

Read More